CONCLUSIONS: Desloratadine therapy, with or without concomitant
corticosteroids, was highly effective in the treatment of allergic rhinitis
in children aged 6 to 12 years. It was also safe and well tolerated.
249 Improved Symptom Relief and Quality of Life WithDesloratadine in Pollen-Induced Allergic RhinitisD. Dumitrascu; University of Medicine and Pharmacy Iuliu Hatieganu,
Cluj Napoca, ROMANIA.
RATIONALE: To evaluate once-daily desloratadine therapy in patients
with pollen-induced allergic rhinitis.
METHODS: In a multicenter, open-label study, 496 patients with pollen-
induced allergic rhinitis were treated with desloratadine 5 mg/day for 14
days. Three visits were scheduled: one within 30 days before patients en-
tered the study (V1), one at baseline (V2), and one at the end of study (V3).
Symptom scores were assessed at V2 and V3 on a scale of 0 to 3 (where
05no symptoms and 35severe symptoms). Patients also rated quality oflife using the Mini Rhinoconjunctivitis QOL Questionnaire
(MiniRQLQ), where 05unaltered and 65extremely altered.RESULTS: After 14 days of desloratadine treatment, the total symptom
score decreased from 9.686 2.55 to 1.856 1.97 (P